Frontlight ResearchEarly access
Taking peoplePhase 3
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis
Key facts
- Who runs it
- Laboratorios Ojer Pharma S.L.
- Where
- Poland10 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 200 people, planned
- Started
- 15 Jan 2025
- Planned end
- 21 Oct 2026
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Participants must have at least 3 recurrences or herpes labialis within the past year
- At least half of the recurrences are preceded by recognizable prodromal symptoms, e.g., itching, redness, burning, tingling or a sense of irritation
- At least half of the prodromes are followed by classical lesions, e.g., ulcer, vesicle, and/or hard crust
- Age ≥18 years at the time of signing the informed consent form
- Able to read, understand, and sign the informed consent document
- Able to understand and follow the study procedures, including completing the study diary
Who cannot take part
- Alcohol or drug abuse
- Simultaneous participation in another clinical trial or participation in any clinical trial involving an Investigational medicinal product within 30 days prior to written informed consent for this trial
- Subjects who have previously enrolled in this study
- Immunocompromised patients or patients receiving immunosuppressive therapy
- Systemic, severe as well as history of uncontrolled chronic disease or a concurrent clinically significant illness, or medical condition, which in the investigator’s opinion, wouldcontraindicate study participation or compliance with protocol -mandated procedures
- Medical or dermatological conditions that interfere with the treatment or assessment of the herpes lesions (e.g., eczema, psoriasis, acne, seborrhoeic dermatitis)
- Known hypersensitivity/allergic reaction to the study drug substance or any of the formulations’ excipients
- Known hypersensitivity to valaciclovir
- History of herpes keratitis
- History of unresponsiveness to acyclovir therapy
- Participant who is unable or is not expected to reliably comprehend or satisfactorily assess a herpetic lesion
- Unlikely to co-operate with the requirements of the study
- Females who are pregnant, breastfeeding, or planning a pregnancy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of Lipovir® Gel compared to Zovirax® Cream on patients with RHL
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Multicenter, randomised, open-label with blind evaluation active and placebo-controlled, non-inferiority clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) on patients with Recurrent Herpes Labialis
- Record updated
- 19 October 2026